# White House

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/white-house
Canonical HTML page: https://getbiobrief.com/entity/white-house

## Timeline

- **2026-03-15**: Market Impact — Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty.
- **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application.
- **2025-12-01**: Grants Rescinded — The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts.
- **2025-08-15**: Workaround Supported — FDA officials appear to support Moderna's plan to use data from a smaller trial as a workaround for control group concerns.
- **2024-01-01**: Collaboration Begins — Moderna starts working with the FDA on the design for its mRNA flu vaccine trials.

## Recent coverage (2 stories)

### Biotech Eyes $1.4B Ebola Funds as US War Bill Tops $87B
2026-06-28 05:57:59 · Sentiment: Neutral · Impact: 7/10 · Sources: 16

The $1.4 billion Ebola component of the White House’s war funding request could accelerate development of new vaccines and antivirals, offering a rare bright spot for biopharma firms amid broader fiscal uncertainty.
Full story: https://getbiobrief.com/story/biotech-1-4b-ebola-war-bill

### FDA Regulatory Volatility and Political Shifts Threaten Moderna’s mRNA Pipeline
2026-03-16 00:16:43 · Sentiment: Bearish · Impact: 8/10 · Sources: 2

Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight.
Full story: https://getbiobrief.com/story/fda-moderna-mrna-regulatory-threat

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.